Comprehensive repository of peer-reviewed clinical trials and preclinical publications investigating Bremelanotide (PT-141).
Two identical, randomized, double-blind, placebo-controlled phase 3 trials (RECONNECT) evaluated the efficacy and safety of subcutaneous bremelanotide (1.75 mg) administered as needed in premenopausal women with hypoactive sexual desire disorder. Bremelanotide significantly increased Female Sexual Function Index desire domain scores (P<0.001) and significantly decreased Female Sexual Distress Scale-Desire/Arousal/Orgasm distress scores compared with placebo.
